Skip to Content

Spectrum Pharmaceuticals, Inc.

Securities Class Action

  • Date:
  • 9/24/2025
  • Company Name:
  • Spectrum Pharmaceuticals, Inc.
  • Stock Symbol:
  • SPPI
  • Class Period:
  • FROM 12/2/2021 TO 9/22/2022
  • Status:
  • Filed

Case Finder

Locate any case using the tools below.

 Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ:SPPI) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Spectrum securities between March 17, 2022 to September 22, 2022, both dates inclusive (the “Class Period”). Investors have until September 24, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.


According to the Complaint, the Company made false and misleading statements to the market. Spectrum’s Pinnacle Study of poziotinib for the treatment of lung cancer was less positive than it portrayed to investors. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period.


If you purchased or otherwise acquired Spectrum shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Spectrum Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: